Epoch Investment Partners Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$98.5M |
| 2 |
Zoetis
ZTS
|
+$60.9M |
| 3 |
Yum! Brands
YUM
|
+$57.1M |
| 4 |
Charles River Laboratories
CRL
|
+$57M |
| 5 |
Applied Materials
AMAT
|
+$55M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$305M |
| 2 |
Microsoft
MSFT
|
+$269M |
| 3 |
NVIDIA
NVDA
|
+$191M |
| 4 |
Eli Lilly
LLY
|
+$184M |
| 5 |
Amazon
AMZN
|
+$139M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.37% |
| 2 | Healthcare | 17.03% |
| 3 | Financials | 13.96% |
| 4 | Industrials | 11.52% |
| 5 | Consumer Discretionary | 10.94% |
Similar funds
Epoch Investment Partners's Q1 2024 Portfolio in Review
As of Q1 2024, Epoch Investment Partners held 434 positions worth $22.5B, up 2.4% from $22B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Epoch Investment Partners withdrew a net $1.53B in Q1 2024, closing 26 positions and reducing 230 holdings. Its most notable exit was Berry Global Group, Inc., an estimated $69.7M position sold in full.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 24% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Epoch Investment Partners opened a new position in Regeneron Pharmaceuticals worth $99.7M.
- Epoch Investment Partners's largest Q1 2024 buy was Regeneron Pharmaceuticals: 103,551 shares worth $99.7M.
- Epoch Investment Partners added most to Zoetis in Q1 2024, an estimated $60.9M increase.
- Epoch Investment Partners's biggest Q1 2024 reduction was Apple, cutting an estimated $305M.
- Epoch Investment Partners fully exited Berry Global Group, Inc. in Q1 2024, selling an estimated $69.7M.
- Epoch Investment Partners's ten largest holdings make up 16% of its $22.5B portfolio in Q1 2024.
- Epoch Investment Partners opened 23 new positions and closed 26 in Q1 2024.
- Epoch Investment Partners's portfolio value rose 2.4% quarter-over-quarter to $22.5B.
Based on Epoch Investment Partners's 13F filing for Q1 2024, filed 14 May 2024.